ST-246 400 mg + ST-246 600 mg + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Orthopoxviral Disease

Conditions

Orthopoxviral Disease

Trial Timeline

Jun 1, 2009 → Jan 1, 2010

NCT ID

NCT00907803

About ST-246 400 mg + ST-246 600 mg + Placebo

ST-246 400 mg + ST-246 600 mg + Placebo is a phase 2 stage product being developed by SIGA Technologies for Orthopoxviral Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00907803. Target conditions include Orthopoxviral Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00907803	Phase 2	Completed	Jun 1, 2009	Jan 1, 2010	Orthopoxviral Disease

Competing Products

1 competing product in Orthopoxviral Disease

See all competitors

Product	Company	Stage	Hype Score
ST-246 Days 1 - 3 + ST-246 Days 11 - 13	SIGA Technologies	Phase 1	19